2300 | Humans |
1328 | Male |
1273 | Female |
995 | Middle Aged |
992 | Aged |
700 | Animals |
640 | Parkinson Disease (physiopathology) |
464 | Parkinson Disease (drug therapy) |
462 | Adult |
326 | Parkinson Disease (complications) |
290 | Parkinson Disease (metabolism) |
290 | Aged, 80 and over |
279 | Parkinson Disease (pathology) |
251 | Parkinson Disease (therapy) |
244 | Parkinson Disease (diagnosis) |
201 | Parkinson Disease (genetics) |
193 | Antiparkinson Agents (therapeutic use) |
188 | Parkinson Disease (psychology) |
179 | Levodopa (therapeutic use) |
171 | Rats |
167 | Case-Control Studies |
166 | Dopamine (metabolism) |
154 | Treatment Outcome |
152 | Disease Models, Animal |
150 | Mice |
144 | Severity of Illness Index |
143 | Parkinson Disease (epidemiology) |
132 | Time Factors |
124 | Neuropsychological Tests |
122 | Brain (metabolism) |
117 | Brain (pathology) |
114 | Parkinson Disease (surgery) |
113 | Parkinson Disease, Secondary (chemically induced) |
112 | Parkinson Disease (diagnostic imaging) |
111 | Levodopa (adverse effects) |
104 | Antiparkinson Agents (adverse effects) |
101 | Risk Factors |
101 | Follow-Up Studies |
101 | Brain (physiopathology) |
98 | Disease Progression |
97 | Analysis of Variance |
94 | Parkinson Disease (etiology) |
91 | Magnetic Resonance Imaging |
83 | Deep Brain Stimulation (methods) |
80 | Retrospective Studies |
78 | Canada |
78 | Adolescent |
75 | Neurons (metabolism) |
74 | Tomography, Emission-Computed |
73 | Corpus Striatum (metabolism) |
72 | Cohort Studies |
70 | Dose-Response Relationship, Drug |
69 | Macaca fascicularis |
68 | Reproducibility of Results |
68 | Psychomotor Performance (physiology) |
66 | Movement (physiology) |
64 | Rats, Sprague-Dawley |
62 | Neurons (physiology) |
62 | Age Factors |
59 | Double-Blind Method |
59 | Dopamine (physiology) |
57 | Immunohistochemistry |
56 | Wolff-Parkinson-White Syndrome (physiopathology) |
54 | Wolff-Parkinson-White Syndrome (surgery) |
54 | Surveys and Questionnaires |
54 | Substantia Nigra (pathology) |
54 | Prevalence |
54 | Neurons (drug effects) |
52 | Quality of Life |
52 | Mice, Inbred C57BL |
52 | Cognition Disorders (etiology) |
51 | Cells, Cultured |
51 | Brain Mapping |
50 | Electrocardiography |
50 | Diagnosis, Differential |
49 | Tremor (physiopathology) |
49 | Brain (diagnostic imaging) |
48 | Molecular Sequence Data |
48 | Models, Biological |
47 | Reference Values |
47 | Prospective Studies |
47 | Neurons (pathology) |
47 | Globus Pallidus (surgery) |
46 | alpha-Synuclein (metabolism) |
46 | Parkinson Disease, Secondary (physiopathology) |
46 | Brain (drug effects) |
45 | Levodopa (pharmacology) |
45 | Corpus Striatum (drug effects) |
45 | Antiparkinson Agents (pharmacology) |
44 | Positron-Emission Tomography |
44 | Dyskinesia, Drug-Induced (physiopathology) |
44 | Child |
42 | Subthalamic Nucleus (physiology) |
42 | Mutation (genetics) |
42 | Dopamine Agents (therapeutic use) |
41 | Reaction Time (physiology) |
41 | Magnetic Resonance Imaging (methods) |
41 | Antiparkinson Agents (administration & dosage) |
41 | Amino Acid Sequence |
40 | Motor Activity (drug effects) |
40 | Globus Pallidus (physiopathology) |
40 | Electromyography |
39 | Subthalamic Nucleus (physiopathology) |
39 | Substantia Nigra (drug effects) |
39 | Protein-Serine-Threonine Kinases (genetics) |
39 | Predictive Value of Tests |
39 | Mutation |
39 | Disability Evaluation |
39 | Cross-Sectional Studies |
39 | Biomechanical Phenomena |
38 | Young Adult |
38 | Behavior, Animal (drug effects) |
37 | United States |
37 | Sensitivity and Specificity |
37 | Longitudinal Studies |
37 | Alzheimer Disease (pathology) |
37 | Algorithms |
36 | Tyrosine 3-Monooxygenase (metabolism) |
36 | Levodopa (administration & dosage) |
36 | Image Processing, Computer-Assisted |
36 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
35 | Psychiatric Status Rating Scales |
35 | Parkinson Disease, Secondary (pathology) |
35 | Dyskinesia, Drug-Induced (etiology) |
35 | Cognition Disorders (diagnosis) |
34 | Tremor (etiology) |
34 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
34 | Dihydroxyphenylalanine (analogs & derivatives) |
34 | Deep Brain Stimulation |
34 | Corpus Striatum (diagnostic imaging) |
34 | Clinical Trials as Topic |
34 | Age of Onset |
34 | Activities of Daily Living |
33 | Ubiquitin-Protein Ligases (metabolism) |
33 | Mice, Knockout |
33 | Genotype |
33 | Functional Laterality (physiology) |
33 | Drug Therapy, Combination |
33 | Alzheimer Disease (metabolism) |
32 | Substantia Nigra (physiopathology) |
32 | Psychomotor Performance |
32 | Phenotype |
32 | Parkinson Disease, Secondary (metabolism) |
32 | Parkinson Disease (rehabilitation) |
32 | Neuroprotective Agents (therapeutic use) |
32 | Dopamine Agonists (therapeutic use) |
31 | Ubiquitin-Protein Ligases (genetics) |
31 | Positron-Emission Tomography (methods) |
31 | Parkinson Disease, Secondary (drug therapy) |
31 | Parkinson Disease (enzymology) |
31 | Dopamine Agents (pharmacology) |
31 | Canada (epidemiology) |
30 | alpha-Synuclein (genetics) |
30 | Substantia Nigra (metabolism) |
30 | Psychomotor Performance (drug effects) |
30 | Neural Pathways (physiopathology) |
30 | Motor Activity (physiology) |
30 | Genetic Predisposition to Disease |
30 | Functional Laterality |
30 | Electrodes, Implanted |
30 | Dementia (pathology) |
30 | Corpus Striatum (physiopathology) |
30 | Basal Ganglia (physiopathology) |
29 | Wolff-Parkinson-White Syndrome (diagnosis) |
29 | Sex Factors |
29 | Electrophysiology |
28 | Neurologic Examination |
28 | Mitochondria (metabolism) |
28 | Mice, Transgenic |
28 | Heart Conduction System (physiopathology) |
28 | Gait Disorders, Neurologic (etiology) |
28 | Corpus Striatum (pathology) |
27 | Statistics, Nonparametric |
27 | Neuroprotective Agents (pharmacology) |
27 | Motor Cortex (physiopathology) |
27 | Models, Neurological |
27 | Dopaminergic Neurons (metabolism) |
27 | Cell Line |
26 | Pilot Projects |
26 | Microelectrodes |
26 | Incidence |
26 | Dopamine Plasma Membrane Transport Proteins (metabolism) |
26 | Adenosine (metabolism) |
26 | Action Potentials (physiology) |
26 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology) |
25 | Putamen (metabolism) |
25 | Phylogeny |
25 | Movement Disorders (physiopathology) |
25 | Motor Activity |
25 | Electric Stimulation Therapy |
25 | Dopamine Agonists (pharmacology) |
25 | Cognition (physiology) |
24 | Stereotaxic Techniques |
24 | REM Sleep Behavior Disorder (diagnosis) |
24 | Posture (physiology) |
24 | Dyskinesia, Drug-Induced (metabolism) |
24 | Dyskinesia, Drug-Induced (drug therapy) |
24 | Dementia (etiology) |
24 | Autoradiography |
23 | Randomized Controlled Trials as Topic |
23 | Protein Binding |
23 | Prognosis |
23 | Neural Pathways (physiology) |
23 | Dopamine Agonists (adverse effects) |
23 | Dopamine Agents (adverse effects) |
23 | Comorbidity |
23 | Brain (physiology) |
23 | Base Sequence |
23 | Antipsychotic Agents (therapeutic use) |
22 | Receptors, Dopamine (drug effects) |
22 | REM Sleep Behavior Disorder (complications) |
22 | Postural Balance (physiology) |
22 | Polysomnography |
22 | Pedigree |
22 | Lewy Bodies (pathology) |
22 | Cerebral Cortex (physiopathology) |
22 | Cell Line, Tumor |
22 | Blotting, Western |
22 | Astrocytes (metabolism) |
22 | Antipsychotic Agents (adverse effects) |
21 | Signal Transduction |
21 | Receptors, Dopamine (metabolism) |
21 | RNA, Messenger (metabolism) |
21 | Parkinson Disease (classification) |
21 | Oxidative Stress |
21 | Movement Disorders (etiology) |
21 | Motor Cortex (physiology) |
21 | Heart Conduction System (surgery) |
21 | Gait Disorders, Neurologic (physiopathology) |
21 | Fluorine Radioisotopes |
21 | Basal Ganglia (pathology) |
21 | Alzheimer Disease (diagnosis) |
20 | Wolff-Parkinson-White Syndrome (complications) |
20 | Regression Analysis |
20 | Parkinson Disease (mortality) |
20 | History, 20th Century |
20 | Gait (physiology) |
20 | Dopamine Plasma Membrane Transport Proteins |
20 | Data Interpretation, Statistical |
20 | Brain Mapping (methods) |
19 | REM Sleep Behavior Disorder (physiopathology) |
19 | Placebo Effect |
19 | Photic Stimulation |
19 | Parkinson Disease (blood) |
19 | Oxidopamine |
19 | Ontario |
19 | Movement |
19 | Movement (drug effects) |
19 | Gene Expression Regulation |
19 | Electric Stimulation |
19 | Alzheimer Disease (physiopathology) |
18 | Statistics as Topic |
18 | Signal Transduction (physiology) |
18 | Selegiline (therapeutic use) |
18 | Reaction Time |
18 | Protein Kinases (genetics) |
18 | Parkinson Disease |
18 | Parkinson Disease (immunology) |
18 | Muscle, Skeletal (physiopathology) |
18 | HEK293 Cells |
18 | Gait |
18 | Evoked Potentials, Motor (physiology) |
18 | Electroencephalography |
18 | Dyskinesia, Drug-Induced (prevention & control) |
18 | Drug Combinations |
18 | Dementia (diagnosis) |
18 | Dementia (complications) |
18 | Cognition Disorders (physiopathology) |
18 | Cell Count |
18 | Cardiac Pacing, Artificial |
18 | Binding Sites |
17 | Tremor (therapy) |
17 | Tomography, Emission-Computed, Single-Photon |
17 | Thalamus (physiopathology) |
17 | Task Performance and Analysis |
17 | Reverse Transcriptase Polymerase Chain Reaction |
17 | Receptors, Dopamine D2 (metabolism) |
17 | Receptors, Dopamine (physiology) |
17 | Protein Structure, Tertiary |
17 | Protein Kinases (metabolism) |
17 | Proportional Hazards Models |
17 | Postoperative Complications |
17 | Parkinsonian Disorders (physiopathology) |
17 | Neurodegenerative Diseases (pathology) |
17 | Nerve Tissue Proteins |
17 | Motor Skills (physiology) |
17 | Memory (physiology) |
17 | Membrane Glycoproteins |
17 | In Vitro Techniques |
17 | Depression (etiology) |
17 | DNA Mutational Analysis |
17 | Cues |
17 | Computer Simulation |
17 | Catheter Ablation |
17 | Carbidopa (therapeutic use) |
17 | Aging (physiology) |
16 | Tremor (diagnosis) |
16 | Thioinosine (analogs & derivatives) |
16 | Syndrome |
16 | Subthalamic Nucleus (surgery) |
16 | Signal Processing, Computer-Assisted |
16 | Risk |
16 | Reactive Oxygen Species (metabolism) |
16 | Rats, Long-Evans |
16 | Phosphorylation |
16 | Parkinson Disease (prevention & control) |
16 | Nerve Tissue Proteins (genetics) |
16 | Movement Disorders (therapy) |
16 | Models, Statistical |
16 | Membrane Transport Proteins |
16 | Logistic Models |
16 | Kinetics |
16 | Genetic Predisposition to Disease (genetics) |
16 | Drug Administration Schedule |
16 | Drosophila Proteins (genetics) |
16 | Dopaminergic Neurons (pathology) |
16 | Deep Brain Stimulation (adverse effects) |
16 | Cerebral Cortex (pathology) |
16 | Cell Survival |
16 | Caudate Nucleus (metabolism) |
16 | Catheter Ablation (methods) |
16 | Carbon Radioisotopes |
16 | Brain Chemistry |
16 | Basal Ganglia (physiology) |
16 | Basal Ganglia (metabolism) |
16 | Attention (physiology) |
16 | Alzheimer Disease (drug therapy) |
15 | Walking (physiology) |
15 | Thalamus (surgery) |
15 | Tetrabenazine (analogs & derivatives) |
15 | Rats, Wistar |
15 | Radiopharmaceuticals |
15 | Radioligand Assay |
15 | Quebec |
15 | Putamen (diagnostic imaging) |
15 | Pregnancy |
15 | Polymorphism, Single Nucleotide |
15 | Parkinsonian Disorders (drug therapy) |
15 | Oxidative Stress (drug effects) |
15 | Neurons (enzymology) |
15 | Neuroimaging |
15 | Nerve Tissue Proteins (metabolism) |
15 | Neostriatum (metabolism) |
15 | Mesencephalon (pathology) |
15 | Mental Status Schedule |
15 | Iron (metabolism) |
15 | Infant |
15 | Dementia (epidemiology) |
15 | Cognition |
15 | Child, Preschool |
15 | Cerebral Cortex (metabolism) |
15 | Brain Chemistry (physiology) |
15 | Behavior, Animal (physiology) |
15 | Autopsy |
15 | Apomorphine (pharmacology) |
14 | Substantia Nigra (cytology) |
14 | Psychotic Disorders (drug therapy) |
14 | Protein Deglycase DJ-1 |
14 | Parkinsonian Disorders (metabolism) |
14 | Outcome Assessment (Health Care) |
14 | Neurodegenerative Diseases (physiopathology) |
14 | Neural Pathways (pathology) |
14 | MPTP Poisoning |
14 | In Situ Hybridization |
14 | Hippocampus (pathology) |
14 | Genome-Wide Association Study |
14 | Fetal Tissue Transplantation |
14 | Electromyography (methods) |
14 | Dopaminergic Neurons (drug effects) |
14 | Dopamine Agonists (administration & dosage) |
14 | Dopamine (deficiency) |
14 | Dementia (psychology) |
14 | Carrier Proteins (metabolism) |
14 | Brain (enzymology) |
14 | Basal Ganglia (drug effects) |
14 | Autonomic Nervous System Diseases (etiology) |
14 | Aging (metabolism) |
13 | Tritium |
13 | Tomography, X-Ray Computed |
13 | Software |
13 | Sleep Wake Disorders (etiology) |
13 | Reward |
13 | Radionuclide Imaging |
13 | RNA, Messenger (genetics) |
13 | Quality of Life (psychology) |
13 | Postural Balance |
13 | Parkinsonian Disorders (pathology) |
13 | Parkinson Disease, Secondary (diagnosis) |
13 | Parkinson Disease (economics) |
13 | Oxidopamine (toxicity) |
13 | Oxidative Stress (physiology) |
13 | Ovariectomy |
13 | Neurodegenerative Diseases (metabolism) |
13 | Nerve Net (physiopathology) |
13 | Monoamine Oxidase Inhibitors (therapeutic use) |
13 | Memory |
13 | Locomotion (drug effects) |
13 | Levodopa (pharmacokinetics) |
13 | Image Interpretation, Computer-Assisted (methods) |
13 | Homovanillic Acid (metabolism) |
13 | Glucose (metabolism) |
13 | Gene Frequency |
13 | Frontal Lobe (physiopathology) |
13 | Dementia (physiopathology) |
13 | Cerebellum (physiopathology) |
13 | Biomarkers |
13 | Benzothiazoles |
13 | Attention |
12 | tau Proteins (genetics) |
12 | Ubiquitination |
12 | Synaptic Transmission (physiology) |
12 | Subthalamic Nucleus (pathology) |
12 | Substantia Nigra (physiology) |
12 | Substantia Nigra (diagnostic imaging) |
12 | Signal Transduction (drug effects) |
12 | Serotonin (metabolism) |
12 | Schizophrenia (drug therapy) |
12 | Rotation |
12 | Risk Assessment |
12 | Receptors, Dopamine D2 (drug effects) |
12 | Raclopride |
12 | REM Sleep Behavior Disorder (epidemiology) |
12 | Patient Selection |
12 | Parkinson Disease (nursing) |
12 | Neurons (cytology) |
12 | Neural Pathways (drug effects) |
12 | Nerve Degeneration (pathology) |
12 | Nerve Degeneration (metabolism) |
12 | Muscle Rigidity (physiopathology) |
12 | Models, Molecular |
12 | Membrane Proteins (genetics) |
12 | Locomotion (physiology) |
12 | Hypokinesia (etiology) |
12 | Globus Pallidus (pathology) |
12 | Genomics |
12 | Gene Expression Profiling |
12 | Evolution, Molecular |
12 | Environmental Exposure |
12 | Environment |
12 | Electric Stimulation Therapy (methods) |
12 | Electric Stimulation (methods) |
12 | Drug Interactions |
12 | Dihydroxyphenylalanine (pharmacokinetics) |
12 | Cocaine (analogs & derivatives) |
12 | Cell Survival (drug effects) |
12 | Carrier Proteins (genetics) |
12 | Carbidopa (administration & dosage) |
12 | Brain Tissue Transplantation |
12 | Biomarkers (metabolism) |
12 | Anxiety (etiology) |
12 | Antioxidants (therapeutic use) |
12 | Amyotrophic Lateral Sclerosis (pathology) |
12 | Action Potentials (drug effects) |
12 | Accidental Falls (prevention & control) |
11 | tau Proteins (metabolism) |
11 | Wolff-Parkinson-White Syndrome (drug therapy) |
11 | Transcription Factors (genetics) |
11 | Thiazoles (therapeutic use) |
11 | Thalamus (physiology) |
11 | Synapses (metabolism) |
11 | Substantia Nigra (enzymology) |
11 | Rural Population |
11 | Research Design |
11 | Random Allocation |
11 | RNA, Messenger (analysis) |
11 | Protein-Serine-Threonine Kinases (metabolism) |
11 | Protein Conformation |
11 | Posture |
11 | Oxidopamine (pharmacology) |
11 | Organ Specificity |
11 | Neuronal Plasticity (physiology) |
11 | Neurologic Examination (drug effects) |
11 | Neural Pathways (metabolism) |
11 | Movement Disorders (drug therapy) |
11 | Mood Disorders (etiology) |
11 | Mitochondria (drug effects) |
11 | Microglia (metabolism) |
11 | Microglia (drug effects) |
11 | Mesencephalon (metabolism) |
11 | Memory Disorders (etiology) |
11 | Levodopa (metabolism) |
11 | Iodine Radioisotopes |
11 | Intracellular Signaling Peptides and Proteins (genetics) |
11 | Inflammation (metabolism) |
11 | Infant, Newborn |
11 | Huntington Disease (physiopathology) |
11 | Globus Pallidus (physiology) |
11 | Globus Pallidus (cytology) |
11 | Genetic Testing |
11 | Enzyme Inhibitors (pharmacology) |
11 | Electroencephalography (methods) |
11 | Dystonia (physiopathology) |
11 | Drosophila melanogaster (genetics) |
11 | Dopamine Antagonists |
11 | Dopamine (analysis) |
11 | Databases, Factual |
11 | Chromatography, High Pressure Liquid |
11 | Cell Death (drug effects) |
11 | Caregivers (psychology) |
11 | Bromocriptine (therapeutic use) |